Comparable genetic alteration profiles between gastric cancers with current and past Helicobacter pylori infection.
Aged
Female
Gastric Mucosa
Gene Amplification
Gene Expression Regulation, Neoplastic
Genome, Human
Helicobacter Infections
/ complications
Helicobacter pylori
High-Throughput Nucleotide Sequencing
Humans
Male
Middle Aged
Mutation
Oncogenes
Point Mutation
Polymorphism, Single Nucleotide
Regression Analysis
Sequence Analysis, DNA
Stomach Neoplasms
/ complications
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
06 12 2021
06 12 2021
Historique:
received:
28
09
2021
accepted:
23
11
2021
entrez:
7
12
2021
pubmed:
8
12
2021
medline:
28
1
2022
Statut:
epublish
Résumé
Gastric cancers can develop even after Helicobacter pylori (H. pylori) eradication in 0.2-2.9% cases per year. Since H. pylori is reported to directly activate or inactivate cancer-related pathways, molecular profiles of gastric cancers with current and past H. pylori infection may be different. Here, we aimed to analyze whether profiles of point mutation and gene amplification are different between the two groups. Current or past infection by H. pylori was determined by positive or negative amplification of H. pylori jhpr3 gene by PCR, and past infection was established by the presence of endoscopic atrophy. Among the 90 gastric cancers analyzed, 55 were with current infection, and 35 were with past infection. Target sequencing of 46 cancer-related genes revealed that 47 gastric cancers had 68 point mutations of 15 different genes, such as TP53 (36%), KRAS (4%), and PIK3CA (4%) and that gene amplification was present for ERBB2, KRAS, PIK3CA, and MET among the 26 genes assessed for copy number alterations. Gastric cancers with current and past infection had similar frequencies of TP53 mutations (38% and 31%, respectively; p = 0.652) and oncogene activation (20% and 29%, respectively; p = 0.444). Gastric cancers with current and past infection had comparable profiles of genetic alterations.
Identifiants
pubmed: 34873204
doi: 10.1038/s41598-021-02761-7
pii: 10.1038/s41598-021-02761-7
pmc: PMC8648804
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
23443Informations de copyright
© 2021. The Author(s).
Références
Eur J Clin Microbiol Infect Dis. 2019 Jan;38(1):55-66
pubmed: 30414090
Gastric Cancer. 2016 Jul;19(3):911-8
pubmed: 26420267
Cancer Res. 2010 Feb 15;70(4):1430-40
pubmed: 20124475
Gastric Cancer. 2017 Mar;20(Suppl 1):8-15
pubmed: 27718135
Gastroenterology. 2014 Aug;147(2):407-17.e3
pubmed: 24786892
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Gastroenterology. 2016 Jan;150(1):64-78
pubmed: 26385073
Lancet. 2008 Aug 2;372(9636):392-7
pubmed: 18675689
Inflamm Res. 2021 Dec;70(10-12):1015-1026
pubmed: 34549319
Gastric Cancer. 2015 Jan;18(1):65-76
pubmed: 24510342
Am J Gastroenterol. 2014 Jan;109(1):60-7
pubmed: 24343545
J Gastroenterol. 2020 Mar;55(3):281-288
pubmed: 31667586
N Engl J Med. 2018 Mar 22;378(12):1085-1095
pubmed: 29562147
N Engl J Med. 2020 Jun 18;382(25):2419-2430
pubmed: 32469182
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
N Engl J Med. 2001 Sep 13;345(11):784-9
pubmed: 11556297
Cancer Lett. 2013 Mar 1;330(1):33-40
pubmed: 23196062
Helicobacter. 2017 Oct;22(5):
pubmed: 28771894
Cell Mol Immunol. 2020 Jan;17(1):50-63
pubmed: 31804619
J Mol Diagn. 2016 Sep;18(5):657-667
pubmed: 27376475
Gastroenterology. 2015 Oct;149(5):1153-1162.e3
pubmed: 26073375
J Gastroenterol Hepatol. 2010 Mar;25(3):544-7
pubmed: 19817964
Aliment Pharmacol Ther. 2016 Feb;43(4):470-81
pubmed: 26669729
NPJ Precis Oncol. 2019 Mar 6;3:7
pubmed: 30854468
Digestion. 2021;102(1):25-32
pubmed: 33070127
Gastroenterology. 2016 May;150(5):1113-1124.e5
pubmed: 26836587
Oncotarget. 2016 Sep 27;7(39):63424-63436
pubmed: 27566570
Epigenomics. 2021 Apr;13(8):565-576
pubmed: 33820444
Clin Cancer Res. 2012 Feb 15;18(4):923-9
pubmed: 22205689